Evidence map›Paper›PMID 42928775›Full record

ReviewDrug design, development and therapy2026

Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation.

Urna Kansakar, Malik Hyman, Enrico Volpe, Pasquale Mone, Yifei Qin, Gaetano Santulli

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Urna KansakarDepartment of Molecular, Cellular and Biomedical Sciences, City University of New York - School of Medicine, New York City, NY, 10031, USA.
Malik HymanDepartment of Molecular, Cellular and Biomedical Sciences, City University of New York - School of Medicine, New York City, NY, 10031, USA.
Enrico VolpeDepartment of Molecular, Cellular and Biomedical Sciences, City University of New York - School of Medicine, New York City, NY, 10031, USA.ORCID 0009-0007-1453-0407
Pasquale MoneDepartment of Medicine and Health Sciences, University of Molise, Campobasso, 86100, Italy.
Yifei QinDepartment of Molecular, Cellular and Biomedical Sciences, City University of New York - School of Medicine, New York City, NY, 10031, USA.
Gaetano SantulliDepartment of Molecular, Cellular and Biomedical Sciences, City University of New York - School of Medicine, New York City, NY, 10031, USA.ORCID 0000-0001-7231-375X

Funding

REGULATION OF THE INSULIN RECEPTOR KINASER01DK033823 · NIDDK · UNIVERSITY OF IOWA · PI KURLAND, IRWIN JACK, PESSIN, JEFFREY E. · 1986 to 2022
$6.7M
Modulation of Mitofusin Activity to Treat Heart DiseaseR01HL159062 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2021 to 2024
$2.6M
Caspase-9 as a nodal point connecting necrotic and apoptotic cell death in myocardial infarctionR01HL164772 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2022 to 2025
$2.5M
Functional role of IP3 receptors in the regulation of cardiac myofibroblastsR01HL146691 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2019 to 2023
$2.1M
Beta Cell Intracellular Calcium and DiabetesR01DK123259 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2020 to 2023
$1.7M
Purposeful Outreach for Diversity and Inclusion of Underrepresented in Medicine (PODIUM) Physician-ScientistsT32HL172255 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Carmen R. Isasi, Marina Reznik · 2024 to 2026
$936k
NHLBI NIH HHS R01 HL146691NHLBI NIH HHS R01 HL159062NHLBI NIH HHS R01 HL164772NHLBI NIH HHS T32 HL172255NIDDK NIH HHS R01 DK033823NIDDK NIH HHS R01 DK123259
6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide, and metabolic dysfunction is increasingly recognized as an important component of its pathophysiology. Clinical evidence supports a role for dysregulated lipid and glucose metabolism in atherosclerosis, heart failure, and cardiometabolic disease, while alterations in amino acid metabolism, mitochondrial energetics, redox signaling, and immunometabolic pathways are supported by growing experimental and observational evidence. Advances in metabolomics, systems biology, and multi-omics approaches have further identified metabolic signatures associated with cardiovascular phenotypes and have provided new insights into pathways regulating endothelial function, vascular inflammation, oxidative stress, and cardiac remodeling. This review synthesizes established clinical evidence and emerging experimental findings on metabolic mechanisms in CVD, with particular emphasis on their potential therapeutic and biomarker implications. We discuss current and investigational strategies targeting lipid and glucose metabolism, mitochondrial dysfunction, oxidative stress, and immunometabolic signaling, while distinguishing clinically validated approaches from those that remain primarily preclinical or hypothesis-generating. Key translational challenges include the complexity and tissue specificity of metabolic networks, limitations of existing experimental models, potential safety liabilities, and the need for longitudinal studies integrating metabolic and clinical phenotypes. Finally, we examine how metabolomics, AI, organ-on-chip models, and systems-level approaches could improve target identification, patient stratification, and therapeutic development. These advances provide a framework for translating mechanistic insights into metabolism-informed cardiovascular therapies and biomarkers, while highlighting the evidence gaps that must be addressed before broader clinical implementation.

Indexed as

Cardiovascular DiseasesAnimalsBiomarkersHumansMetabolomicsMultiomicsOxidative StressBiomarkerscardiovascular diseasemetabolic pathwaysmetabolomicsprecision medicinetherapeutic targets

Identifiers

PMID42928775
PMCPMC13695912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.